Iconic’s lead clinical-stage program is a novel recombinant human chimeric protein therapeutic, hI-con1, licensed from Yale University. hI-con1 binds tissue factor, a promoter of inflammation and angiogenesis, key
Apricus CEO Richard Pascoe noted that the company is excited to have completed the first of several product shipments of Vitaros to different territories in Europe in 2014.
Under the agreement, Astellas will pay $7.3m to the settling parties. The Department of Justice had investigated Astellas for alleged off-label promotion of MYCAMINE for pediatric use, a
This is currently being investigated by Member State authorities and updates will be provided as more information becomes available. Italian law enforcement authorities are currently investigating the theft
The actions taken are consistent with AMRI’s ongoing efforts to consolidate its facility resources to more effectively utilize its discovery and development resource pool and to further reduce
AKB-6548, a once-daily, oral investigational therapy, is designed to achieve a coordinated and natural increase in red blood cell production and iron utilization that is similar to the
RLB Holdings managing partner and co-founder Lydia Bartoszek said: "The vision of Kineta-RLB is to progress the clinical development in high need areas with the hope of improving
Following this the Consumer Healthcare division of Sanofi Korea is making a major launch of Probi´s gut health product, Probi Digestisstarting in April 2014. Probi has already delivered
New participant Novo Ventures and existing investor Third Rock Ventures co-led this round of financing, which also included founding investor SV Life Sciences. Novo Ventures senior partner Dr
Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess FE under its pending Abbreviated New Drug Application (ANDA)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.